HIV-1 Vaccine Trial in Women
Author Information
Author(s): Lewis David J., Fraser Carol A., Mahmoud Abdel N., Wiggins Rebecca C., Woodrow Maria, Cope Alethea, Cai Chun, Giemza Rafaela, Jeffs Simon A., Manoussaka Maria, Cole Tom, Cranage Martin P., Shattock Robin J., Lacey Charles J.
Primary Institution: Centre for Infection & Immunity, Division of Clinical Sciences, St George's, University of London, United Kingdom
Hypothesis
Repeated delivery of gp140 may facilitate antigen uptake and presentation at the vaginal mucosal surface.
Conclusion
The vaginal gp140 vaccine candidate was safe but did not induce local or systemic immune responses in healthy women.
Supporting Evidence
- The vaccine was well tolerated with no serious adverse events.
- Participants received nine doses of the vaccine over three weeks.
- Immunological responses were measured but none were detected.
Takeaway
The study tested a new HIV vaccine given in the vagina, but it didn't help the body fight the virus.
Methodology
A phase 1 double-blind randomised controlled trial with 22 healthy female volunteers receiving either the vaccine or placebo.
Limitations
The study did not detect any immune responses, which may be due to the lack of adjuvants or the method of delivery.
Participant Demographics
Healthy women aged 18-45, predominantly white ethnicity.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website